2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Apoptosis
  3. Antibody-Drug Conjugates (ADCs) VEGFR Apoptosis
  4. Bevacizumab vedotin

Bevacizumab vedotin 是一种抗体偶联药物 (ADC)。Bevacizumab vedotin 可阻断 VEGF/VEGFR 通路以发挥抗血管生成作用。Bevacizumab vedotin 对癌细胞具有抗增殖作用，可促进癌细胞凋亡 (Apoptosis)、阻滞癌细胞周期，且对乳腺癌细胞具有抗迁移活性。Bevacizumab vedotin 可用于胶质瘤、肝细胞癌、乳腺癌的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bevacizumab vedotin

Bevacizumab vedotin Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货
1 mg ￥5950
询问价格 & 货期
5 mg 询价 询问价格 & 货期

* Please select Quantity before adding items.

Customer Review

Bevacizumab vedotin 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer[1].

体外研究
(In Vitro)

Bevacizumab vedotin (1 mg; 72-120 h) 具有较高的血清稳定性[1]。
Bevacizumab vedotin (30-165 min) 会在组织蛋白酶 B 的介导下快速、完全释放其 MMAE 载荷[1]。
Bevacizumab vedotin (0-10 μg/mL; 48 h) 可强效抑制 U87、HepG2 和 MCF-7 细胞的增殖， IC50 值分别为 14.1712 μg/mL、0.6483 μg/mL 和 0.1442 μg/mL[1]。
Bevacizumab vedotin (1 μg/mL; 48 h) 可在处理 48 h 后诱导 U87、HepG2 和 MCF-7 细胞发生凋亡[1]。
Bevacizumab vedotin (0.1-20 μg/mL; 48 h) 处理 48 h 后可诱导 U87 和 HepG2 细胞发生 G1 期细胞周期阻滞[1]。
Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) 可以浓度和时间依赖的方式抑制 MCF-7 细胞迁移，下调 MCF-7 细胞中 VEGF-A 的表达[1]。
Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) 表现出抗血管生成活性，减少 HUVEC 小管形成 (连接点和分支)，下调 HUVEC 细胞中 VEGF-A 的表达，并上调 VEGFR-2 的表达[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bevacizumab vedotin 相关抗体:

Cell Proliferation Assay[1]

Cell Line: U87 , HepG2 , MCF-7 cells
Concentration: 0, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 5, 10 μg/mL
Incubation Time: 48 h
Result: Inhibited proliferation of all three cell lines.
Reached an IC50 of 14.1712 μg/mL for U87 cells.
Reached an IC50 of 0.6483 μg/mL for HepG2 cells.
Reached an IC50 of 0.1442 μg/mL for MCF-7 cells.

Apoptosis Analysis[1]

Cell Line: U87 , HepG2 , MCF-7 cells
Concentration: 1 μg/mL
Incubation Time: 48 h
Result: Promoted apoptosis in all three cell lines.
Achieved a pro-apoptotic rate of 113% relative to the control group for U87 cells.
Achieved a pro-apoptotic rate of 304% relative to the control group for HepG2 cells.
Achieved a pro-apoptotic rate of 288% relative to the control group for MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: U87 , HepG2 cells
Concentration: 0.1-20 μg/mL
Incubation Time: 48 h
Result: Induced G1 phase cell cycle arrest in U87 and HepG2 cells.

Cell Migration Assay [1]

Cell Line: MCF-7 cells
Concentration: 0, 0.01, 0.02, 0.05, 0.1 μg/mL
Incubation Time: 0 h, 12 h, 24 h, 36 h and 48 h
Result: Enhanced concentration-dependent inhibition of MCF-7 cell migration with increasing incubation time.

Western Blot Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.01, 0.05, 0.1 μg/mL
Incubation Time: 48 h
Result: Caused concentration-dependent downregulation of VEGF-A expression in MCF-7 cells.

Western Blot Analysis[1]

Cell Line: HUVEC cells
Concentration: 0.1, 0.5, 1 μg/mL
Incubation Time: 48 h
Result: Caused concentration-dependent downregulation of VEGF-A expression in HUVEC cells.
Caused concentration-dependent upregulation of VEGFR-2 expression in HUVEC cells.
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Bevacizumab vedotin 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bevacizumab vedotinAntibody-Drug Conjugates (ADCs)VEGFRApoptosisAntibody-Drug ConjugatesVascular endothelial growth factor receptorAntibody-drug Conjugategliomahepatocellular carcinomabreast cancerU87 cellsHepG2 cellsMCF-7 cells
Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Bevacizumab vedotin
目录号：
HY-185208
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z